SNTI · Categories · Form 4

SNTI - SEC Form 4 insider transactions

Senti Biosciences Inc. (SNTI) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for SNTI

• 90d
  Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 10,757 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 90d
  CEO Lu Timothy K covered exercise/tax liability with 80,666 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 126d
  Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 1,384 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 126d
  CEO Lu Timothy K covered exercise/tax liability with 4,191 shares, decreasing direct ownership by 0.58% to 720,249 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 323d
  SEC Form 4 filed by Director Baum Bryan Daniel

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 347d
  SEC Form 4 filed by Director Collins James J.

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 347d
  SEC Form 4 filed by Director Hsiung Feng

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 347d
  SEC Form 4 filed by Director Schulz Fran

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 347d
  SEC Form 4 filed by Director Cooperstone Brenda

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 347d
  SEC Form 4 filed by Director Tang Donald F

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 347d
  SEC Form 4 filed by Director Mathers Edward T

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 453d
  Large owner Celadon Partners Spv 24 converted options into 9,777,000 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 454d
  Large owner New Enterprise Associates 15, L.P. converted options into 3,333,000 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 454d
  Large owner Bayer Healthcare Llc converted options into 2,222,000 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Director Mathers Edward T

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  Pres. & Chief Med. & Dev. Off. Rajangam Kanya converted options into 33,000 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Director Schulz Fran

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Director Collins James J.

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Director Tang Donald F

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Director Cooperstone Brenda

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Director Hsiung Feng

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 455d
  SEC Form 4 filed by Chief Financial Officer Cross John Harry Iii

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 456d
  Pres. & Chief Med. & Dev. Off. Rajangam Kanya was granted 78,363 shares, increasing direct ownership by 909% to 86,984 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 456d
  CEO and Interim PFO and PAO Lu Timothy K was granted 642,358 shares, increasing direct ownership by 783% to 724,440 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 488d
  CEO Lu Timothy K sold $18,339 worth of shares (4,467 units at $4.11), decreasing direct ownership by 5% to 82,082 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 488d
  Pres. & Chief Med. & Dev. Off. Rajangam Kanya sold $6,074 worth of shares (1,479 units at $4.11), decreasing direct ownership by 15% to 8,621 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 545d
  SEC Form 4 filed by Large owner Bayer Healthcare Llc

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 546d
  SEC Form 4 filed by Director Tang Donald F

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 546d
  SEC Form 4 filed by Director Schulz Fran

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 546d
  SEC Form 4 filed by Pres. & Chief Med. & Dev. Off. Rajangam Kanya

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 697d
  SEC Form 4 filed by Director Mathers Edward T

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 697d
  SEC Form 4 filed by Director Farokhzad Omid

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 697d
  SEC Form 4 filed by Director Collins James J.

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 697d
  SEC Form 4 filed by Director Cooperstone Brenda

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 858d
  Rajangam Kanya was granted 101,000 shares (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 858d
  Lu Timothy K was granted 306,000 shares, increasing direct ownership by 55% to 865,496 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 858d
  Knobelman Deborah was granted 101,000 shares, increasing direct ownership by 337% to 131,000 units (SEC Form 4)

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1084d
  SEC Form 4 filed by Mathers Edward T

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1084d
  SEC Form 4 filed by Berland Susan D

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1084d
  SEC Form 4 filed by Collins James J.

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1084d
  SEC Form 4 filed by Cooperstone Brenda

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1084d
  SEC Form 4 filed by Farokhzad Omid

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1223d
  SEC Form 4 filed by Lee Philip J

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1223d
  SEC Form 4 filed by Rajangam Kanya

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1223d
  SEC Form 4 filed by Knobelman Deborah

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)
• 1223d
  SEC Form 4 filed by Lu Timothy K

  4 - Senti Biosciences, Inc. (0001854270) (Issuer)

Other SNTI categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends